A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms dal-OUTCOMES
  • Sponsors Roche
  • Most Recent Events

    • 09 Aug 2017 This study has been discontinued in Belgium.
    • 16 Nov 2016 Results from nested case-control analysis assessing the association of lipoprotein with major adverse CV events presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 18 Jul 2016 According to a DalCor Pharmaceuticals media release, data from this study was published in Circulation, Cardiovascular Genetics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top